Dizhe Pharmaceuticals (688192.SH): Positive top-line results from international multicenter phase III clinical trial of Shuwozhe monotherapy for EGFRexon20ins non-small cell lung cancer.

Di Zhe Pharmaceuticals (688192.SH) announced that the company's independently developed product Shuwuzhe (ZEGFROVY, generic name: Shuwotini tablet) has achieved the primary research endpoint and obtained positive top-line results in the international multicenter Phase III clinical study "Wukong28" for the first-line treatment of epidermal growth factor receptor (EGFR) exon 20 insertion mutation (exon20ins) advanced non-small cell lung cancer (NSCLC). It is the first and only oral targeted drug to achieve positive results in international multicenter randomized controlled Phase III clinical studies targeting EGFRexon20ins NSCLC in the world.